Antibiotic resistance patterns of methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus isolates in keratitis: Insights from an 11-year analysis

角膜炎中甲氧西林敏感金黄色葡萄球菌和甲氧西林耐药金黄色葡萄球菌分离株的抗生素耐药模式:一项为期11年的分析的启示

阅读:4

Abstract

PURPOSE: To determine the prevalence and antibiotic resistance trends in methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) keratitis over an 11-year study period. DESIGN: Retrospective study. METHODS: Microbiology records of patients with culture-positive Staphylococcus aureus (SA) keratitis presenting to a tertiary eye center over 11 years were retrospectively reviewed. Susceptibility data to commonly used topical antibiotics were obtained. RESULTS: MSSA accounted for 58.4% of SA keratitis, while MRSA constituted 41.6%. No significant change in prevalence was observed for MRSA or MSSA keratitis over the study period. Both MSSA and MRSA had a higher proportion of isolates resistant to antibiotics in the fluoroquinolone group, compared to chloramphenicol, cefazolin, and vancomycin. A greater proportion of MRSA isolates were resistant to cefazolin (15.4%) compared to MSSA (0.5%). Almost all isolates were susceptible to vancomycin, except an isolated MRSA case in 2022. There was no significant increase in the proportion of MSSA and MRSA isolates resistant to antibiotics, except for the proportion of MSSA isolates resistant to chloramphenicol ( R2= 0.81), and MRSA isolates to cefazolin ( R2= 0.74). CONCLUSION: No significant increase in the prevalence of MRSA keratitis over the study period was observed. A high proportion of resistance of MSSA isolates to commonly used topical antibiotics challenges the conventional notion that MRSA is more resistant to antibiotics than MSSA. The observed proportion of SA isolates resistant to fluoroquinolones and the increasing percentage of isolates resistant to cefazolin emphasize the need for continued surveillance to strategize empirical treatment policies. Minimal resistance to vancomycin supports its continued use as a reserve drug in cases of severe multi-drug resistant SA keratitis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。